Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer

Yasunori Emi, Yoshihiro Kakeji, Hideo Baba, Teruyoshi Ishida, Yoshihiko Maehara

Research output: Contribution to journalReview article

Abstract

5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combination chemotherapy has been developed. Although several phase III studies were reported in the 1990s, a standard chemotherapeutic regimen has not been established worldwide. Recently, a newly developed anticancer agent, Paclitaxel, can be clinically used for advanced gastric cancer either as a single agent or in combination with such as 5-FU, cisplatin, and TS-1. It may well further improve the quality of life and prolong the survival of patients with gastric cancer. Further assessment for the well design phase III clinical trials will be necessary to establish the availability of such combination modalities for the treatment of advanced, recurrent gastric cancer.

Original languageEnglish
Pages (from-to)1978-1981
Number of pages4
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume31
Issue number12
Publication statusPublished - Jan 1 2004

Fingerprint

Paclitaxel
Combination Drug Therapy
Stomach Neoplasms
Fluorouracil
Phase III Clinical Trials
Antineoplastic Agents
Cisplatin
Quality of Life
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer. / Emi, Yasunori; Kakeji, Yoshihiro; Baba, Hideo; Ishida, Teruyoshi; Maehara, Yoshihiko.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 31, No. 12, 01.01.2004, p. 1978-1981.

Research output: Contribution to journalReview article

Emi, Y, Kakeji, Y, Baba, H, Ishida, T & Maehara, Y 2004, 'Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 31, no. 12, pp. 1978-1981.
Emi, Yasunori ; Kakeji, Yoshihiro ; Baba, Hideo ; Ishida, Teruyoshi ; Maehara, Yoshihiko. / Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2004 ; Vol. 31, No. 12. pp. 1978-1981.
@article{7c1965c8be0d4a16864bfe7be6e20c03,
title = "Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer",
abstract = "5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combination chemotherapy has been developed. Although several phase III studies were reported in the 1990s, a standard chemotherapeutic regimen has not been established worldwide. Recently, a newly developed anticancer agent, Paclitaxel, can be clinically used for advanced gastric cancer either as a single agent or in combination with such as 5-FU, cisplatin, and TS-1. It may well further improve the quality of life and prolong the survival of patients with gastric cancer. Further assessment for the well design phase III clinical trials will be necessary to establish the availability of such combination modalities for the treatment of advanced, recurrent gastric cancer.",
author = "Yasunori Emi and Yoshihiro Kakeji and Hideo Baba and Teruyoshi Ishida and Yoshihiko Maehara",
year = "2004",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "1978--1981",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Current combination chemotherapy containing paclitaxel for advanced, recurrent gastric cancer

AU - Emi, Yasunori

AU - Kakeji, Yoshihiro

AU - Baba, Hideo

AU - Ishida, Teruyoshi

AU - Maehara, Yoshihiko

PY - 2004/1/1

Y1 - 2004/1/1

N2 - 5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combination chemotherapy has been developed. Although several phase III studies were reported in the 1990s, a standard chemotherapeutic regimen has not been established worldwide. Recently, a newly developed anticancer agent, Paclitaxel, can be clinically used for advanced gastric cancer either as a single agent or in combination with such as 5-FU, cisplatin, and TS-1. It may well further improve the quality of life and prolong the survival of patients with gastric cancer. Further assessment for the well design phase III clinical trials will be necessary to establish the availability of such combination modalities for the treatment of advanced, recurrent gastric cancer.

AB - 5-FU has been a key chemotherapeutic agent in the treatment of advanced or recurrent gastric cancer. In order to enhance the effect of 5-FU, biochemical modulation or combination chemotherapy has been developed. Although several phase III studies were reported in the 1990s, a standard chemotherapeutic regimen has not been established worldwide. Recently, a newly developed anticancer agent, Paclitaxel, can be clinically used for advanced gastric cancer either as a single agent or in combination with such as 5-FU, cisplatin, and TS-1. It may well further improve the quality of life and prolong the survival of patients with gastric cancer. Further assessment for the well design phase III clinical trials will be necessary to establish the availability of such combination modalities for the treatment of advanced, recurrent gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=16544378872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16544378872&partnerID=8YFLogxK

M3 - Review article

C2 - 15570924

AN - SCOPUS:16544378872

VL - 31

SP - 1978

EP - 1981

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -